Lupin launches Mycophenolic Acid Delayed-Release Tablets USP

Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced the launch of Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg. Lupin's alliance partner Concord Biotech Limited (Concord) had received approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, is the generic equivalent of Myfortic® Delayed-Release Tablets, 180 mg, and 360 mg, of Novartis Pharmaceuticals Corporation, and are indicated for:

• Prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant.
• Use in combination with cyclosporine and corticosteroids.

Mycophenolic Acid Delayed-Release Tablets USP (RLD: Myfortic®) had annual sales of approximately USD 156 million in the U.S. 

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Read also: Lupin Gets USFDA EIR For Aurangabad Facility